Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02723539
Other study ID # MBN-101-202
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 6, 2017
Est. completion date July 26, 2019

Study information

Verified date June 2020
Source Microbion Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, multi-center study, in patients with moderate to severe diabetic foot infection (DFI), that will be conducted in two parts. In Part I, patients will be enrolled into 1 of 3 escalating dose cohorts at a ratio of 3:1 (Active to Placebo). In Part II, patients will be randomized in a 1:1 ratio (Active to Placebo) based on the optimal dose demonstrated in Part I. Patients will be randomized to receive either topical application of MBN-101 or topical application of vehicle, applied directly to the target site, 3 times per week, for a minimum of 14 days and up to a maximum of 21 days. All patients will also receive systemic antibiotic treatment.


Description:

This is a randomized, double-blind, placebo-controlled, multi-center study that will be conducted in two parts. In Part I, patients will be enrolled into escalating dose cohorts (150, 375, or 600 µg/mL) (N=16/cohort) at a ratio of 3:1 (Active to Placebo). In Part II, patients will be randomized in a 1:1 ratio (Active to Placebo) based on the optimal dose demonstrated in Part I.

Patients with diabetes mellitus and a foot infection with an Infectious Disease Society of America (IDSA) infection severity rating of moderate or severe will be eligible for the trial. Both inpatients and outpatients are eligible if they meet all inclusion/exclusion criteria, however all enrolled patients must remain in-hospital for the first 24 hours after initial dosing. Patients with a need for surgical therapy (e.g., incision and drainage or removal of necrotic tissue) beyond standard bedside wound debridement should not be enrolled.

Patients will be randomized to receive either topical application of MBN-101 or topical application of vehicle, applied directly to the target site, 3 times per week, for a minimum of 14 days and up to a maximum of 21 days. The determination to stop topical antibiotic therapy will be at the discretion of the principal investigator, and should be based on the resolution of findings of infection. All patients will also receive systemic antibiotic treatment based on the protocol defined algorithm. Systemic antibiotic therapy should continue until, but not beyond, the resolution of findings of infection, as outlined in the 2012 IDSA clinical practice guideline for the diagnosis and treatment of diabetic foot infections,


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date July 26, 2019
Est. primary completion date November 1, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Has diabetes mellitus, according to the American Diabetes Association (ADA) criteria

- Has a foot infection as defined by the IDSA guidelines, with a severity rating of moderate or severe

- Either no current or recent (within 72 hours) antibiotic therapy for the DFI,

- Has documented adequate arterial perfusion in the affected limb (either palpable dorsalis pedis or posterior tibial pulses, or normal Doppler wave forms, or a toe blood pressure = 45 mm Hg, or an ankle-brachial index (ABI) of >0.6)

Exclusion Criteria:

- Proven or highly suspected, involvement of bone (i.e., osteomyelitis)

- More than one concurrent, infected, diabetic foot ulcer

- Hemoglobin A1c > 11 on the day of presentation

- Requirement for ongoing immunosuppressive therapy (topical or inhaled corticosteroids are permitted)

- Serum creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST) or Alkaline Phosphatase >2 times the upper limit of the normal range of the local testing laboratory

- Absolute neutrophil count <1000

- Any condition that has required treatment with any other bismuth containing compound within the last 2 weeks (i.e., Kaopectate or Pepto-Bismol)

- Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months

- Need for any surgical therapy beyond debridement to treat the diabetic foot ulcer (e.g., incision and drainage, removal of necrotic tissue)

- Planned lower extremity amputation that will include their infected ulcer

- Known allergy to bismuth and/or MBN-101 excipients (methylcellulose, Tween 80 (polysorbate 80))

- Female patients who are pregnant, lactating, or who have a positive serum human chorionic gonadotropin (pregnancy) as determined by laboratory testing

- Immunocompromised due to illness or organ transplant

- History of any type of cancer (excluding non-melanoma localized skin cancer or completely excised and cured carcinoma-in-situ of uterine cervix)

- History of major medical noncompliance

- Other medical conditions which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MBN-101
Topical application
Placebo
Topical application

Locations

Country Name City State
United States Limb Preservation Platform, Inc Fresno California
United States Futuro Clinical Trials, LLC McAllen Texas

Sponsors (1)

Lead Sponsor Collaborator
Microbion Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants with treatment-related adverse events Safety and tolerability will be assessed by treatment-related adverse events From the start of dosing upto 4 weeks following the completion of dosing
Primary Proportion of participants who are clinically cured Clinical cure is defined as the resolution of clinical signs and symptoms of infection 2 weeks following the end of treatment (EOT) 2 weeks following completion of dosing (up to 5 weeks)
Secondary Proportion of participants who are microbiologically cured Microbiological cure is defined as the eradication of baseline pathogens 2 weeks following the end of treatment (EOT). 2 weeks following completion of dosing (up to 5 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT05613985 - PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers N/A
Recruiting NCT03964571 - Human and Bacterial Protease Activity as Prognostic Tool of Foot Infections in Diabetic Patients N/A
Completed NCT03230175 - Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01) Phase 2
Completed NCT05616351 - Antibiotic Therapy in Infections of the Diabetic Foot Syndrome
Recruiting NCT05948592 - Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection Phase 2
Recruiting NCT04714411 - Real-World Efficacy and Safety Analysis of Omadacycline for the Treatment of Diabetic Foot Infections and Acute Osteomyelitis
Completed NCT05243810 - EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers N/A
Recruiting NCT05610865 - Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers Phase 1
Recruiting NCT04450693 - Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II) Phase 3
Recruiting NCT05369052 - Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI) Phase 3
Completed NCT04440839 - Implementation of Telemedicine for Patient With Lower Extremity Wounds N/A
Withdrawn NCT04289948 - Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes Phase 1/Phase 2
Completed NCT03495349 - Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.
Completed NCT05564728 - Diabetes Footcare Companion App for Patients and Carers
Withdrawn NCT03354806 - Peripheral Analgesia in Painful Diabetic Neuropathy N/A
Completed NCT01590758 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Completed NCT01594762 - Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers Phase 3
Active, not recruiting NCT05174806 - Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients Phase 2
Recruiting NCT04141787 - Ceftriaxone as Home IV for Staph Infections Phase 4